Journal of Medicinal Chemistry p. 7188 - 7211 (2016)
Update date:2022-08-15
Topics:
Kilchmann, Falco
Marcaida, Maria J.
Kotak, Sachin
Schick, Thomas
Boss, Silvan D.
Awale, Mahendra
G?nczy, Pierre
Reymond, Jean-Louis
Here we report the discovery of a selective inhibitor of Aurora A, a key regulator of cell division and potential anticancer target. We used the atom category extended ligand overlap score (xLOS), a 3D ligand-based virtual screening method recently developed in our group, to select 437 shape and pharmacophore analogs of reference kinase inhibitors. Biochemical screening uncovered two inhibitor series with scaffolds unprecedented among kinase inhibitors. One of them was successfully optimized by structure-based design to a potent Aurora A inhibitor (IC50 = 2 nM) with very high kinome selectivity for Aurora kinases. This inhibitor locks Aurora A in an inactive conformation and disrupts binding to its activator protein TPX2, which impairs Aurora A localization at the mitotic spindle and induces cell division defects. This phenotype can be rescued by inhibitor-resistant Aurora A mutants. The inhibitor furthermore does not induce Aurora B specific effects in cells.
View MoreContact:86-512-87182056
Address:No.128 Fangzhou Rd, Suzhou Industrial Park, China, 215125, China
Jinan Decheng Hemu Medical Technology Co.,Ltd.
Contact:+86-531-68650525
Address:NO.554 Zhengfeng Road High-new Technology Development Zone
website:http://www.lonwinchem.com
Contact:Tel: 86-21-59858395
Address:No#966,Huaxu Road,Shanghai 201702,P.R.China
Jiaxing Anrui Material Technology Co., Ltd.
Contact:86-573-82651652 13305832579
Address:Room 407, Technology Building, 1369 Chennan Road, Jiaxing City, Zhejiang, China
GuangZhe ANFA chemical co.,Ltd
Contact:86-579-87262335
Address:Guangzhe industrial area ,shaowu city ,Fujiang
Doi:10.1002/cbdv.201800599
(2019)Doi:10.1021/jacs.9b06410
(2019)Doi:10.1016/j.tetlet.2007.07.128
(2007)Doi:10.1002/adsc.200700504
(2008)Doi:10.1016/j.tet.2011.10.006
(2011)Doi:10.1002/anie.200702563
(2007)